https://www.selleckchem.com/pr....oducts/sar131675.htm
To determine whether robotic-assisted lobectomy (RAL) affects perioperative outcomes and long-term efficacy in non-small cell lung cancer (NSCLC) patients, compared with traditional video-assisted lobectomy (VAL). RAL is a promising treatment for NSCLC. However, its efficacy has not been fully evaluated. A single-center, open-labeled prospective randomized clinical trial was launched in May 2017 to compare the efficacy of RAL and VAL. By May 2020, 320 patients were enrolled. The perioperative results of RAL and VAL were compared. The
Like
Comment
Share
